Update in Hematology
Authors: Thomas G. DeLoughery
Journal: Annals of Internal Medicine (2007)

Updates20 November 2007Update in HematologyThomas G. DeLoughery, MD*Thomas G. DeLoughery, MD*From Oregon Health & Science University, Portland, Oregon.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-147-10-200711200-00008 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This Update in Hematology reviews the past year's most important articles relevant to hematology. The Table(1, 2) summarizes changes to clinical practice that should emerge from these articles. Table. Changes to Clinical Practice Emerging from Articles Important to Hematologists in 2007Anticoagulation Eriksson BI, Borris LC, Dahl OE, et al.; ODIXa-HIP Study Investigators. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006;114:2374-81. [PMID: 17116766]Question: What dose of rivaroxaban, a direct factor Xa inhibitor, is safest and most effective for ...References1. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-17. [PMID: 16531616] CrossrefMedlineGoogle Scholar2. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233-43. [PMID: 16990386] CrossrefMedlineGoogle Scholar3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86. [PMID: 11786451] CrossrefMedlineGoogle Scholar4. The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group. Lancet. 1987;2:1351-4. [PMID: 2890951] MedlineGoogle Scholar5. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293:2352-61. [PMID: 15900005] CrossrefMedlineGoogle Scholar6. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995 May 18;332(20):1330-5. [PMID: 7715641] Google Scholar7. Dameshek W, Miller ED. The megakaryocytes in idiopathic thrombocytopenic purpura, a form of hypersplenism. Blood. 1946;1:27-51. CrossrefMedlineGoogle Scholar8. Newland A, Caulier MT, Kappers-Klunne M, Schipperus MR, Lefrere F, Zwaginga JJ, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol. 2006;135:547-53. [PMID: 17061981] CrossrefMedlineGoogle Scholar9. Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007;109:4739-41. [PMID: 17327409] CrossrefMedlineGoogle Scholar10. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-90. [PMID: 9718377] CrossrefMedlineGoogle Scholar11. Foley RN, Parfrey PS, Morgan J, Barré PE, Campbell P, Cartier P, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58:1325-35. [PMID: 10972697] CrossrefMedlineGoogle Scholar12. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16:2180-9. [PMID: 15901766] CrossrefMedlineGoogle Scholar13. Pfeffer MA; TREAT Executive Committee. An ongoing study of anemia correction in chronic kidney disease [Letter]. N Engl J Med. 2007;356:959-61. [PMID: 17329707] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Thomas G. DeLoughery, MDAffiliations: From Oregon Health & Science University, Portland, Oregon.Disclosures:Consultancies: GlaxoSmithKline. Honoraria: Baxter, GlaxoSmithKline, Sanofi-Aventis.Corresponding Author: Thomas G. DeLoughery, MD, Divisions of Hematology/Medical Oncology and Laboratory Medicine, Oregon Health & Science University, Hematology L586, 3181 SW Sam Jackson Park Road, Portland, OR 97239-3098; e-mail, delought@ohsu.edu.*Adapted for publication in Annals of Internal Medicine by Jennifer Fisher Wilson and Michael Berkwits, MD, MSCE. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 20 November 2007Volume 147, Issue 10Page: 717-724KeywordsAspirinHemorrhageHeparinHeparin-induced thrombocytopeniaLow molecular weight heparinPlateletsProphylaxisSurgeryThrombinThrombosis ePublished: 20 November 2007 Issue Published: 20 November 2007 Copyright & PermissionsCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...